TY - JOUR
T1 - Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors
AU - Dageforde, Leigh Anne
AU - Vachharajani, Neeta
AU - Tabrizian, Parissa
AU - Agopian, Vatche
AU - Halazun, Karim
AU - Maynard, Erin
AU - Croome, Kristopher
AU - Nagorney, David
AU - Hong, Johnny C.
AU - Lee, David
AU - Ferrone, Cristina
AU - Baker, Erin
AU - Jarnagin, William
AU - Hemming, Alan
AU - Schnickel, Gabriel
AU - Kimura, Shoko
AU - Busuttil, Ronald
AU - Lindemann, Jessica
AU - Florman, Sander
AU - Holzner, Matthew L.
AU - Srouji, Rami
AU - Najjar, Marc
AU - Yohanathan, Lavanya
AU - Cheng, Jane
AU - Amin, Hiral
AU - Rickert, Charles A.
AU - Yang, Ju Dong
AU - Kim, Joohyun
AU - Pasko, Jennifer
AU - Chapman, William C.
AU - Majella Doyle, Maria B.
N1 - Publisher Copyright:
© 2020 American College of Surgeons
PY - 2021/4
Y1 - 2021/4
N2 - Background: Combined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA. Study Design: Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis. Results: Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001). Conclusions: Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. Within Milan criteria, liver transplant for cHCC-CCA and HCC result in similar overall survival, justifying consideration of transplantation due to the higher chance of cure with liver transplantation in this traditionally excluded population.
AB - Background: Combined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA. Study Design: Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis. Results: Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001). Conclusions: Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. Within Milan criteria, liver transplant for cHCC-CCA and HCC result in similar overall survival, justifying consideration of transplantation due to the higher chance of cure with liver transplantation in this traditionally excluded population.
UR - http://www.scopus.com/inward/record.url?scp=85099617048&partnerID=8YFLogxK
U2 - 10.1016/j.jamcollsurg.2020.11.017
DO - 10.1016/j.jamcollsurg.2020.11.017
M3 - Article
C2 - 33316425
AN - SCOPUS:85099617048
SN - 1072-7515
VL - 232
SP - 361
EP - 371
JO - Journal of the American College of Surgeons
JF - Journal of the American College of Surgeons
IS - 4
ER -